


Pharmaceutical Economics and Policy

Stuart O. Schweitzer

*DOC | *audiobook | ebooks | Download PDF | ePub*



#1443286 in Books Stuart O Schweitzer 2006-11-02Original language:EnglishPDF # 1 6.20 x .50 x 9.30l, 1.39 #File Name: 0195300955336 pagesPharmaceutical Economics and Policy | File size: 25.Mb

Stuart O. Schweitzer : Pharmaceutical Economics and Policy before purchasing it in order to gage whether or not it would be worth my time, and all praised Pharmaceutical Economics and Policy:

10 of 10 people found the following review helpful. Review of Pharmaceutical Economics and PolicyBy A CustomerI commend the author's attempt to provide a comprehensive review of pharmaceutical economics and policy in less than three hundred pages. This book is an interesting read and is accessible to those of us who are not economists. However, I would not recommend this book to others due to the facts that (1) the author is inconsistent in referencing

the literature and (2) he often fails to present alternative interpretations of the empirical evidence. For example, the author uses evidence of price discrimination to demonstrate the "importance of consumer demand" in the pricing of pharmaceuticals and, by extension, the presence of competition in the pharmaceutical market (pgs. 103-105). However, he fails to point out that price discrimination by pharmaceutical companies reduces consumer surplus, a direct benefit of competitive markets. In addition, the book contains many typos that may prove distracting to some readers. 2 of 2 people found the following review helpful. A Product of Laziness By Dr Moreault's almost ludicrous to claim this book is updated. I read the older version (published around 1997) because it was the only one that was available at my University library. I thought it would be perfect as research for an essay I was planning on writing, so I ordered the updated 2007 version assuming it would be essentially the same format but with updated statistics and information. Anyway long story short I had the unpleasant experience of being reminded that 'assume' makes and a** out of u and me. The 2007 version had hardly been updated. Save for a few new chapters it is almost exactly the same. The author still cites the exact same studies from the late 1980s and early 90s, some with extremely small sample sizes, as if these are still relevant, as well as providing a plethora of old statistics that ceased to be of any use 6 or 7 years ago (unless you happen to be a historian). In short this book can hardly be called a scholarly achievement. It's fine if you want a brief overview of the history and economic functioning of the pharmaceutical industry, without getting too hung up on whether the information is up-to-date, but if you want to use it to aid in writing an essay on microeconomics it will probably be a waste of your time and money. The author obviously did not put enough effort updating his book. Another thing people might have a problem with is that the author tends to side with the pharmaceutical industry on most issues (ie pharmaceutical price controls are detrimental, the drug approval process is too strict etc.). I don't in principle have any problem with advocating free market solutions to economic problems, but some may be irked by the one-sided presentation. 11 of 11 people found the following review helpful. Regrettably, out of date... By Dr. van der Linden---...since its publication in 1997, for during the interval we've had (among other developments):(1) The Food and Drug Administration Modernization Act (FDAMA '97),(2) The promulgation of the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals (2002), and(3) The federal Department of Health and Human Services (DHHS) formally weighing in with their final "anti-kickback" guidance from the Office of their Inspector General (OIG), incidentally shutting the door between pharmaceuticals marketing and the drug manufacturers' "support" of continuing medical education (CME) on April 28, 2003.(4) New concerns regarding drug safety issues (both pre- and post-marketing) have been raised by way of the COX-2 NSAID crisis, particularly by Merck's defalcations in the suppression of adverse events data in the 2000 publication of their VIGOR trial results (see Waxman's editorial in *The New England Journal of Medicine*, June 23, 2005;352[25]:2576-2578), and have invoked structural and procedural changes in the FDA's Office of New Drugs (OND) the end of which is not yet in sight.(5) Medicare Part "D" has gone into effect, with NICE long-term implications for future impact upon the pharmaceutical industry in these United States. Things have *changed,* folks. There's ten years' worth of critically important regulatory and pharmacoeconomic changes that neither the author nor the rest of the industry could have taken into consideration back when the galleys of this book were returned to the publisher. To the best of my knowledge, there is still no other source of information on the subject as ambitious (and as competently written) as is Dr. Schweitzer's work. Both author and publisher must certainly be aware of the fact that there is a need (and a definite market) for a new edition.---

The pharmaceutical industry is praised as a world leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. At the same time, the industry is also criticized for its marketing and pricing practices and for its apparent anticompetitive responses to generic competition. Even its research and development priorities are criticized as being too closely driven by the goal of maximizing shareholder value, rather than the health of the public. Unfortunately, many of the critics of the industry fail to understand the complexities of the industry and its role in the nation's healthcare system. This book uses the tools of economic analysis to explore the conflicting priorities and aims of the pharmaceutical industry, from both an American and worldwide perspective. This is the second edition of a uniquely comprehensive and balanced discussion of pharmaceutical policy issues. All the chapters of the former edition have been fully re-written and extensively updated. In addition, the book includes six new chapters on emerging topics such as the broadened role of FDA regulations and the increasing diversity of the industry. An entire chapter is devoted to the biotechnology industry and one to alternative medicines, often called "nutraceuticals." Another new chapter discusses segments of the industry that specialize in particular activities including generic drugs and drug delivery systems. The recent controversial expansion of Medicare to cover outpatient drugs is discussed in depth. The introduction is also updated to address the volatile pace of pharmaceutical innovation and how the pharmaceutical industry has responded to the emergence of managed care.

"Dr. Schweitzer...has performed a valuable service by writing a broad overview of these topics....The chapter on pharmaceutical regulation and cost containment and the roles of the different players in this area was quite

interesting...The chapter devoted solely to patents was also most welcome....Very valuable book. It contains current information, delivered in an evenhanded way, on a wide range of topics. It is a useful overview of an important area of health care."--Mark J. Goldberger, M.D., M.P.H., The New England Journal of Medicine"Schweitzer's book is a much-needed, ambitious contribution to the field and an important starting point for graduate-level studies....Pharmaceutical Economics and Policy is an important, useful contribution to the literature."--American Journal of Health-System Pharmacy"This book is easy to read and provides an excellent overview of the pharmaceutical industry. The economic framework used to analyze the industry contributes substantially to an understanding of this industry. This book makes a useful contribution to anyone interested in understanding pharmacoeconomic theory and the characteristics of the pharmaceutical industry."--Inquiry"In summary, this book is both an interesting and valuable contribution to the policy discussion involving pharmaceuticals in this country."--Journal of Economic Literature"...this book is a must-have if you are seriously interested in the domestic and international pharmaceutical industry. Its greatest strength is concise yet comprehensive coverage of many of the important issues relating to the industry."--Journal of Public Health Policy

About the Author
Stuart O. Schweitzer is Professor of Health Economics, University of California, Los Angeles.